Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation and immunotherapy combo shows promise in shrinking lung tumors before surgery

NCT ID NCT06877299

Recruiting now Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jan 08, 2026 · Last updated Jun 12, 2026 · Updated 36 times

Summary

This study tests a new approach for people with stage II to III non-small cell lung cancer that can be surgically removed. Before surgery, patients receive low-dose radiation plus focused high-dose radiation, followed by a combination of an immunotherapy drug (tislelizumab) and standard chemotherapy. The goal is to see if this treatment can shrink or eliminate the tumor before surgery, improving outcomes. The study involves 30 adults aged 18 to 75.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, China, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER